The group's principle activity is to develop therapeutic medical devices for the treatment of mitral regurgitation and heart failure. The group's products include Coapsys(R) Device, iCoapsys(TM) Device, TRACE Trial, VIVID Feasibility and RESTOR-MV Centers. The group operates from United States.
Executive Information
Name
Title
Email
Jim Hickey
Dir., CEO, Pres.
N/A
Cyril Schweich
Co - Founder, CTO, VP - Clinical, Regulatory Affairs
